Nasdaq nmra.

The company’s shares trade on the Nasdaq under the stock symbol “NMRA.” Neumora is a new-ish company, having emerged with a $400 million Series A round of financing in 2021 after its initial formation in 2019. But the company’s history goes back further. Neumora represents the combination of five acquisitions, each bringing drug ...

Nasdaq nmra. Things To Know About Nasdaq nmra.

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA Get Free Report) traded up 4.6% on Friday . The stock traded as high as $11.21 and last traded at $11.09. 32,521 shares were traded during... Share to Feed. Insider Buying: Neumora Therapeutics, Inc. (NASDAQ:NMRA) Major Shareholder Purchases 30,192 Shares of Stock Ticker Report • …Posted by Defense World Staff on Nov 24th, 2023. Shares of Neumora Therapeutics, Inc. ( NASDAQ:NMRA – Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed ...Shares of Neumora Therapeutics Inc (NASDAQ: NMRA) were trading lower on Tuesday, a month after the company announced its IPO on the NASDAQ exchange. RBC Capital Markets On Neumora Therapeutics.View the latest NMRA social media trends at MarketBeat. Skip to main content. S&P 500 4,514.02. DOW 34,947.28. QQQ 386.04. 3 large caps with red hot RSIs with upside. ... This page (NASDAQ:NMRA) was last updated on 11/18/2023 by MarketBeat.com Staff. Adding Choose a watchlist: Watchlist. Cancel AddingNeumora Therapeutics, Inc. (NASDAQ: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the pricing of its initial public offering of ...

Neumora hopes to list its shares on Nasdaq under the symbol NMRA. JP Morgan, BofA Securities, Stifel, Guggenheim Securities, RBC Capital Markets and William Blair are serving a joint bookrunners.7 hari yang lalu ... ... Nasdaq MarketSIte · Trust Center · Newsletters · Chrome Extension · Privacy Policy · Cookies · Legal; Cookies Settings. © 2023, Nasdaq, Inc. All ...Neumora Therapeutics, Inc. (NASDAQ: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the pricing of its initial public offering of ...

Research Neumora Therapeutics' (Nasdaq:NMRA) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance ...20 Nov 2023 ... NMRA:NSQNASDAQ. Neumora Therapeutics Inc. Actions. Add to watchlist; Add ... Its other product candidates include NMRA-511, NMRA-266, NMRA-NMDA, ...

ImmunityBio (NASDAQ:IBRX) and Neumora Therapeutics (NASDAQ:NMRA) are both medical companies, but which is the superior stock?We will contrast the two businesses based on the strength of their valuation, media sentiment, community ranking, earnings, institutional ownership, profitability, risk, dividends and …WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will participate in two investor conferences in November: Guggenheim Healthcare Talks 5th Annual INI …NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia WATERTOWN, Mass., Nov. 27, 2023 (GLOBE ...NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia WATERTOWN, Mass., Nov. 27, 2023 (GLOBE ...Successfully completed initial public offering: In September 2023, Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception, Neumora has raised over $850 million to further its mission to confront the global brain disease ...

Neumora Therapeutics press release (NASDAQ:NMRA): Q3 GAAP EPS of -$1.14 misses by $0.74. $519.5 million in cash, cash equivalents and marketable securities expected to support operations into 2026.

Sep 15, 2023 · The shares are expected to begin trading on the Nasdaq Global Select Market on September 15, 2023 under the ticker symbol “NMRA.”

Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) last issued its earnings results on Wednesday, November 1st. The company reported ($1.14) earnings per share for the quarter, missing the ...Canopy Growth Corporation Common Shares. $1.165 -0.175 -13.06%. NVDA. NVIDIA Corporation Common Stock. $449.995 +1.295 +0.29%. Neumora Therapeutics, Inc. Common Stock (NMRA) Advanced Charting ...Neumora Therapeutics (NASDAQ: NMRA), a biotech company focused on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, went public on September 15th with ...Neumora Therapeutics (NASDAQ:NMRA) shares are up over 15% this morning. 10 Top Losers Vivos Therapeutics (NASDAQ: VVOS ) stock is plummeting nearly 34% after a massive rally yesterday on FDA news .About Robert Lenz, M.D., Ph.D., executive vice president, head of research and development Dr. Rob Lenz is executive vice president, head of research and development at Neumora.Neumora Therapeutics Inc (NASDAQ: NMRA) gained 15.4% to $14.00 in pre-market trading. Neumora Therapeutics recently initiated a Phase 1 single ascending dose / multiple ascending dose study of ...

NVDA. NVIDIA Corporation Common Stock. $449.995 +1.295 +0.29%. Neumora Therapeutics, Inc. Common Stock (NMRA) Advanced Charting - Nasdaq offers …2 days ago · According to 6 analysts, the average rating for NMRA stock is "Strong Buy." The 12-month stock price forecast is $22.0, which is an increase of 84.56% from the latest price. Neumora Therapeutics, Inc. ( NASDAQ:NMRA – Get Free Report) Director Kristina Burow bought 43,082 shares of the business’s stock in a transaction dated Monday, November 6th. The stock was ...WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ...What happenedShares of Neumora Therapeutics (NASDAQ: NMRA) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence. The ...How much institutional buying is happening at Neumora Therapeutics? Institutional investors have bought a total of 11,743,056 shares in the last 24 months. This purchase volume represents approximately $165.69M in transactions. This page (NASDAQ:NMRA) was last updated on 11/28/2023 by MarketBeat.com Staff.Based on analysts offering 12 month price targets for NMRA in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .

When is Neumora Therapeutics (NASDAQ:NMRA) reporting earnings? A. Neumora Therapeutics ( NMRA) is scheduled to report earnings on February 15, 2024. The last reported earnings were for reported on ... Several big names on Wall Street, including BofA Securities, JPMorgan, Stifel, Guggenheim, and RBC Capital started coverage on Neumora Therapeutics Inc (NASDAQ: NMRA) with a Buy (or equivalent) rating today.The stock is down over 30% since its IPO last month.

View NMRA historial stock data and compare to other stocks and exchanges. ... Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.Member FINRA / SIPC / NYSE / NASDAQ / CBOE EDGX. Webull offers NMRA Ent Holdg (NMRA) historical stock prices, in-depth market analysis, NASDAQ: NMRA real-time stock quote data, in-depth charts, free NMRA options chain data, and a fully built financial calendar to help you invest smart. Buy NMRA stock at Webull. (NASDAQ: NMRA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.21%. What is NMRA's Price Target? According to 5 Wall Street analyst s that have issued a 1 year NMRA price target, the average NMRA price target is $22.00 , with the highest NMRA stock price forecast at $26.00 and the lowest NMRA stock ...Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the ...Neumora Therapeutics, Inc. (NASDAQ: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the pricing of its initial public offering of ...Neumora Therapeutics. 's revenue in 2023 is N/A.. On average, 1 Wall Street analysts forecast NMRA's revenue for 2026 to be $3,327,405,256, with the lowest NMRA revenue forecast at $3,327,405,256, and the highest NMRA revenue forecast at $3,327,405,256.A high-level overview of Neumora Therapeutics, Inc. (NMRA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and …

Neumora Therapeutics Inc. began trading on the Nasdaq Friday around 12:30 p.m. under the ticker symbol "NMRA." The Watertown startup sold 14.7 million shares at $17 each, the midpoint of its range.

Fiscal Q3 2023 ended 9/30/23. Get the latest Neumora Therapeutics Inc (NMRA) real-time quote, historical performance, charts, and other financial information to help you make …

Watch Nasdaq's Neumora Therapeutics [NMRA] Rings the Nasdaq Opening Bell on Livestream.com.View live Neumora Therapeutics, Inc. chart to track its stock's price action. Find market predictions, NMRA financials and market news.10 Okt 2023 ... Market Conditions: The broader stock market experienced a mixed situation on October 2, 2023. This can be attributed to concerns such as ...Its other product candidates include NMRA-511, NMRA-266, NMRA-NMDA, NMRA-CK1d, NMRA-NLRP3, and NMRA-GCase. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-266 is a positive allosteric modulator of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia and other neuropsychiatric …Neumora Therapeutics Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.Minim, Inc. (NASDAQ: MINM) gained 29.3% to $1.19 in pre-market trading after gaining over 13% on Wednesday. ... (NASDAQ: NMRA) gained 15.4% to $14.00 in pre-market trading. Neumora Therapeutics ...Neumora Therapeutics, Inc. (NASDAQ:NMRA) as filed to raise $100 million in an IPO of its common stock, according to an SEC S-1 registration statement.Nov 9, 2023 · Neumora Therapeutics, Inc. ( NASDAQ:NMRA – Get Free Report) Director Kristina Burow bought 43,082 shares of the business’s stock in a transaction dated Monday, November 6th. The stock was ... Shares of Neumora Therapeutics (NMRA 0.41%) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence.WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ...Neumora Therapeutics is a biotech company located in Massachusetts, United States, which is part of the Healthcare sector, and is traded under the ticker NMRA on the NASDAQ exchange. Neumora Therapeutics stock last closed at $11.69 , down 1.35% from the previous day, and has decreased N/A in one year.Neumora Therapeutics Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.

WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the third quarter ended September 30, 2023 and provided a general business update.View the latest NMRA social media trends at MarketBeat. Skip to main content. S&P 500 4,514.02. DOW 34,947.28. QQQ 386.04. 3 large caps with red hot RSIs with upside. ... This page (NASDAQ:NMRA) was last updated on 11/18/2023 by MarketBeat.com Staff. Adding Choose a watchlist: Watchlist. Cancel AddingFounded Date 2019. Founders Carol Suh, Mike Poole, Paul L Berns. Operating Status Active. Last Funding Type Series B. Stock Symbol NASDAQ:NMRA. Company Type For Profit. Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science …Instagram:https://instagram. what should i invest in on cash appspyg dividendvoo compositionnysearca jepi Navacaprant is an investigational once-daily oral medication that is designed to modulate the dopamine and reward processing pathways. Its other product candidates include NMRA-511, NMRA-266, NMRA-NMDA, NMRA-CK1d, NMRA-NLRP3, and NMRA-GCase. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). michael jordan autographed cardpaper trading options on webull The Watertown, MA-based Neumora Therapeutics (NASDAQ:NMRA), a Phase 3 biotech developing therapies for brain diseases has priced its initial public offering of 14.71 million shares of its common ... vanguard balanced etf Neumora Therapeutics, Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics, Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.2 days ago · View Neumora Therapeutics, Inc NMRA investment & stock information. Get the latest Neumora Therapeutics, Inc NMRA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.